In a significant move within Morocco’s pharmaceutical sector, Laprophan, a prominent pharmaceuticals group, has sought legal counsel from Asafo & Co. for its acquisition of Amanys Pharma from SPE Capital and Proparco.
The strategic acquisition between Laprophan and Amanys Pharma, backed by an investment from a consortium of investors led by Mediterrania Capital Partners (MCP), is poised to redefine the pharmaceutical landscape in Morocco and extend its impact across Africa. The collaboration aims to establish a diversified pharmaceutical group, leveraging the specialized and complementary divisions of both Laprophan and Amanys. It is important to note that the success of this acquisition is contingent upon securing the necessary regulatory approvals.
The legal advisory team from Asafo & Co. team was led by partners Patrick Larrivé and Mouna Boubia, the team included the expertise of associate Donatien Michel, as well as associates Zineb Benabdellah, Assia Khaldi, Noor Rachid, Christy Komba–Malonga, and Souhail Sassi.
Deloitte Maroc, represented by Julien Leyrit, contributed as the financial advisor to Laprophan.